Skip to content
Saturday 18 July 2026EN · DE
City PM

European business, markets and politics

  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Wednesday 17 June 2020 7:56 am

‘Best news so far’: Matt Hancock hails steroid drug that can combat coronavirus

By: Reuters

Add as a preferred source on Google
'Best news so far': Matt Hancock hails steroid drug that can combat coronavirus
'Best news so far': Matt Hancock hails steroid drug that can combat coronavirus

Health secretary Matt Hancock today hailed the use of a steroid drug called dexamethasone for treating coronavirus patients as the best news so far of the outbreak.

Trial results announced on Tuesday showed dexamethasone, which is used to reduce inflammation in other diseases such as arthritis, reduced death rates by around a third among the most severely ill COVID-19 patients admitted to hospital.

“It does increase your chances of survival quite significantly,” Health Secretary Matt Hancock told Sky News. “It is one of the best pieces of news we’ve had through this whole crisis.”

He said that the R-rate was below 1 in all regions but did not clarify if he was speaking about England or the entire United Kingdom.

Yesterday the government gave the green light for the NHS to begin using dexamethasone immediately to treat coronavirus patients.

That followed an Oxford University clinical trial showing the steroid drug reduced the risk of death significantly in patients badly struck by coronavirus.

Read more: UK scientists make ‘major breakthrough’ as common steroid found to cut coronavirus death rate

The anti-inflammatory steroid drug has now been approved to treat all UK hospitalised coronavirus patients requiring oxygen, including those on ventilators. 

The dexamethasone trial is the first anywhere in the world to show a treatment significantly impacts coronavirus mortality.

The government had already moved to stockpile the drug, meaning it has enough to treat more than 200,000 people. Hancock has said it could save thousands of lives.

Read more

GSK says AI is reshaping drug pipeline as Nuvalent deal hits shares

GSK said total sales fell by two per cent in the third quarter

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Politics

Related Topics

  • Coronavirus

Trending Articles

  • Revealed: KPMG and Deloitte offer bumper redundancy packages to slash headcount

  • James Watt offers to buy back Brewdog

  • Citroën 2CV returns as a £13,000 electric car, and the timing is no accident

  • Motsepe backed to succeed Fifa’s Infantino by South African minister

  • Brewdog owner shrugs off James Watt takeover bid

More from City PM

  • GSK says AI is reshaping drug pipeline as Nuvalent deal hits shares

    Tech
    GSK said total sales fell by two per cent in the third quarter
  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

    Business Wire
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

    Business Wire
  • Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

    Business Wire
  • Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy · Facebook